Metformin in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT00247117 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2006-10-09

No results posted yet for this study

Summary

The purpose of this study is to examine the effect of metformin on biochemical and histological findings in NAFLD patients with insulin resistance syndrome.

Conditions

Interventions

DRUG

Metformin

Sponsors & Collaborators

  • Kaplan Medical Center

    lead OTHER

Principal Investigators

  • Stephen D Malnick, MD · Kaplan Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Completion
2005-08-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00247117 on ClinicalTrials.gov